TheStreet's Jim Cramer says many people felt Mannkind's inhaled insulin drug Afrezza would fail and as a result, 28-percent of the float was short and any good news would get the stock going. On the other hand, those who believe in the drug say this is the beginning of a major move for the stock since Mannkind has already spent a "fortune" developing Afrezza. However, Cramer says he is completely neutral and sometimes it's better to admit you don't know where something is going.

At the time of publication, Cramer was long ___.

More from Video

Learn Options Trading from the Najarian Brothers, the Best in the Business

Learn Options Trading from the Najarian Brothers, the Best in the Business

Jim Cramer: Kimberly Clark's Quarter Was Better Than Procter & Gamble's

Jim Cramer: Kimberly Clark's Quarter Was Better Than Procter & Gamble's

Video: Jim Cramer on What Trade Tariffs and Rising Rates Mean for Stocks

Video: Jim Cramer on What Trade Tariffs and Rising Rates Mean for Stocks

The Stock Market Isn't Rigged, Just Look At The Odds (VIDEO)

The Stock Market Isn't Rigged, Just Look At The Odds (VIDEO)

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options